Showing 511-520 of 8348 results for "".
The Future of Ocular Imaging?
https://crstoday.com/crst-issues/2018-aug/the-future-of-ocular-imaging/43766/The ability of a single OCT instrument to image the whole eye could provide new insights and make testing quicker.The Future of Corneal Surgery
https://crstoday.com/crst-issues/jan-2024/the-future-of-corneal-surgery/45195/An Inside Look at Innovations in Ophthalmology
https://crstoday.com/crst-supplements/an-inside-look-at-innovations-in-ophthalmology-october-2022/an-inside-look-at-innovations-in-ophthalmology-5/44864/Innovation Journal Club explores recently published and presented data around innovations in eye care with a focus on how they might shape real-world practice.An Inside Look at Innovations in Ophthalmology
https://crstoday.com/crst-supplements/an-inside-look-at-innovations-in-ophthalmology-september-2022/an-inside-look-at-innovations-in-ophthalmology-3/44838/Innovation Journal Club explores recently published and presented data around innovations in eye care with a focus on how they might shape real-world practice.This Month's Videos on Eyetube.net
https://crstoday.com/topics/general/this-months-videos-on-eyetubenet-13/42825/This Month's Videos on Eyetube.net
https://crstoday.com/topics/general/this-months-videos-on-eyetubenet-10/42751/Minimizing the Effect of Babel
https://crstoday.com/crst-issues/2019-jan/minimizing-the-effect-of-babel/43878/Inconsistent terminology renders the challenging subject of astigmatism more complex.This Month's Videos on Eyetube.net
https://crstoday.com/topics/general/this-months-videos-on-eyetubenet/42394/Clinical Guidelines for Surface Ablation
https://crstoday.com/crst-issues/sept-2020/clinical-guidelines-for-surface-ablation/44319/Advances have made PRK a mainstream option once again.Newly Approved Glaucoma Therapy Increases Options for Patients and Providers
https://crstoday.com/topics/comorbidities/newly-approved-glaucoma-therapy-increases-options-for-patients-and-providers/43625/Netarsudil, a ROCK inhibitor, represents the first novel class of IOP-lowering medications to reach the glaucoma market since the 1990s.